Usefulness of Corifollitropin alfa as alternative to conventional daily rFSH protocols in oocyte donors undergoing pituitary suppression with Medroxiprogesterona acetate (MPA).

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506908-66-00

Acronym

2304-VLC-051-JG

Enrollment

318

Registered

2023-12-13

Start date

2025-06-17

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility

Brief summary

Number of MII oocytes and mature oocyte rate

Interventions

DRUGCORIFOLLITROPIN ALFA

DRUGFOLLITROPIN BETA

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of MII oocytes and mature oocyte rate	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026